Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Joinn Laboratories (China) CoSHSE:603127 +3.72%78 EBITDA Margin % is 81.08% as of Mar. 2026, which is 109% above its 10-year median of 38.81. GuruFocus rates SHSE:603127 with a GF Score™ of 78/100 and a GF Value™ of ¥17.43 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Joinn Laboratories (China) Co ranks better than 92.61% on this metric.
Joinn Laboratories (China) Co (SHSE:603127) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Joinn Laboratories (China) Co EBITDA Margin % Related Terms
Joinn Laboratories (China) Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Joinn Laboratories (China) Co EBITDA Margin % Chart
SHSE:603127 vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Joinn Laboratories (China) Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Joinn Laboratories (China) Co EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Joinn Laboratories (China) Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Joinn Laboratories (China) Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Joinn Laboratories (China) Co (SHSE:603127) has a EBITDA Margin % of 81.08% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Joinn Laboratories (China) Co and its competitors. This is 109% above median its historical median of 38.81. Over the past decade, Joinn Laboratories (China) Co's EBITDA Margin % has ranged from 11.73 to 60.17. According to the industry distribution chart, Joinn Laboratories (China) Co ranks #15 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 7.4%.
Is Joinn Laboratories (China) Co's EBITDA Margin % too high?
Joinn Laboratories (China) Co's current EBITDA Margin % of 81.08% is 109% above median its 10-year median of 38.81. Over the past 10 years, this metric has ranged from a low of 11.73 to a high of 60.17. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.43. Joinn Laboratories (China) Co's value of 81.08% is 1393.2% above this industry median. Based on the distribution chart, Joinn Laboratories (China) Co ranks #15 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Joinn Laboratories (China) Co has a GF Score™ of 78/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Joinn Laboratories (China) Co's EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Joinn Laboratories (China) Co ranks #15 out of 203 companies for EBITDA Margin %. This places Joinn Laboratories (China) Co in the top 7% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 5.43. Joinn Laboratories (China) Co's value of 81.08% is 1393.2% above this benchmark. Historically, Joinn Laboratories (China) Co's own EBITDA Margin % has ranged from 11.73 to 60.17 over the past decade. While the company's 10-year median is 38.81 vs. the industry median of 5.43, Joinn Laboratories (China) Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.43, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Joinn Laboratories (China) Co's current EBITDA Margin % of 81.08% is 1393.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Joinn Laboratories (China) Co and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Joinn Laboratories (China) Co's current EBITDA Margin % is 81.08%, which is 109% above median its own 10-year median of 38.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Joinn Laboratories (China) Co stock overvalued right now?
Based on GuruFocus' analysis, Joinn Laboratories (China) Co (SHSE:603127) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥17.43, compared to a current price of ¥41.54 — trading 138.3% above its estimated fair value. The current EBITDA Margin % is 81.08%, which is 109% above median its 10-year median of 38.81 and 1393.2% above the Medical Diagnostics & Research industry median of 5.43. Joinn Laboratories (China) Co's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Joinn Laboratories (China) Co (SHSE:603127), the current EBITDA Margin % is 81.08% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Joinn Laboratories (China) Co (SHSE:603127) Overvalued in 2026?
Based on GuruFocus' analysis, Joinn Laboratories (China) Co stock appears to be overvalued.
The current stock price of ¥41.54 is trading 138.3% above its estimated GF Value™ of ¥17.43.
GuruFocus considers Joinn Laboratories (China) Co to be Significantly Overvalued.
Key valuation signals for SHSE:603127:
EBITDA Margin %: 81.08% (109% above median its 10-year median of 38.81)
GF Value™: ¥17.43 vs. price of ¥41.54 (138.3% above fair value)
Industry Position: 1393.2% above the Medical Diagnostics & Research median (#15 of 203)
No single metric tells the full story. See the SHSE:603127 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Joinn Laboratories (China) Co Ltd is a PRC-based company, along with its subsidiary, it is engaged in contract research organisation (CRO) services. It operates in three segments: Non-clinical studies services offer drug safety assessment, drug metabolism and pharmacokinetics (DMPK) studies, and pharmacology and efficacy studies; Clinical trial & related services provide clinical CRO services, co-managed phase I clinical research units, and bioanalytical servicesl services; and Sales of research models engages in the design, production, breeding and sales of research models, non-human primates and rodents. The majority of revenue comes from the Non-Clinical studies services. Its geographical areas are China, the United States, and Other countries, of which the majority are from China.
78GF Score
Get the complete analysis for SHSE:603127
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603127 has been successfully added to your 
